| Document |
Document Title |
|
WO/2018/166468A1 |
Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linke...
|
|
WO/2018/166494A1 |
The present disclosure relates to the use of a compound as shown in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetes mellitus, or the use of same in the...
|
|
WO/2018/165933A1 |
Polypeptide for regulating saccharometabolism and uses thereof in the preparation of drugs for treating diseases related to saccharometabolism. The polypeptide can reduce blood sugar, can promote insulin secretion, can be used in the pre...
|
|
WO/2018/159522A1 |
Provided is a food composition for preventing or alleviating metabolic syndrome, the food composition containing, as active ingredients, a 67 kDa laminine receptor (67LR) agonist and a sulfur-containing compound found from an allium plan...
|
|
WO/2018/157202A1 |
The present invention is a delivery system for sublingual and/or buccal delivery comprising at least one functional oil (i.e. acting as an oil delivery base); at least one surfactant; and at least one pharmaceutically active agent. The i...
|
|
WO/2018/155622A1 |
By suppressing the loss of living cells or living tissue during the production of a PVA gel that contains living cells or living tissue, the present invention addresses the problem of supplying a cell- or tissue-embedding device that has...
|
|
WO/2018/153849A1 |
The present invention relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relate...
|
|
WO/2018/148666A1 |
It is disclosed herein that a FAK inhibitor induces conversion of acinar cells into beta cells. Methods are provided for increasing beta cell proliferation by administering an effective amount of a FAK inhibitor to a subject in need ther...
|
|
WO/2018/147300A1 |
Provided is a somatostatin receptor subtype 2 agonist. A compound disclosed in the present invention that is represented by general formula (I) (wherein each symbol has the same meaning as defined in the description) or a salt thereof is...
|
|
WO/2018/146473A1 |
The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysacchar...
|
|
WO/2018/136890A1 |
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...
|
|
WO/2018/130174A1 |
Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method th...
|
|
WO/2018/129395A1 |
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
|
|
WO/2018/122409A1 |
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...
|
|
WO/2018/123910A1 |
[Problem] To provide a composition with which it is possible to promote increase in androgen. [Solution] Provided is a composition for promoting increase in androgen, and which contains compound K. This composition for promoting increase...
|
|
WO/2018/124009A1 |
The purpose of the present invention is to provide a prophylactic or ameliorating agent for hypothermia which is effective against hypothermia. Specifically provided is a prophylactic or ameliorating agent for hypothermia which compris...
|
|
WO/2018/118691A1 |
Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA.
|
|
WO/2018/114670A1 |
The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4- yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, interme...
|
|
WO/2018/103726A1 |
Provided are a crystal form of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquin
azolin-4(3H)-one represented by Formula I, a preparation method and a use thereof. The present invention belongs ...
|
|
WO/2018/100776A1 |
Provided is a technique for decomposing a resveratrol glycoside, preferably decomposing a resveratrol glycoside and an isoflavone glycoside, and thus promoting aglycone production to thereby increase the absorbability thereof into a livi...
|
|
WO/2018/099363A1 |
Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expres...
|
|
WO/2018/098501A1 |
The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a the...
|
|
WO/2018/091153A1 |
The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SER...
|
|
WO/2018/090851A1 |
Disclosed is the use of FBP aldolase in the preparation of a drug activating AMPK. Also disclosed are the uses of FBP aldolase in the preparation of a drug for inhibiting cholesterol synthesis, a drug for reducing fatty acid synthesis, a...
|
|
WO/2018/078049A1 |
The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanoph...
|
|
WO/2018/077795A1 |
The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.
|
|
WO/2018/068120A1 |
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound; the use of said compound; a synthetic intermediate in the preparation of comp...
|
|
WO/2018/071058A1 |
Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods e...
|
|
WO/2018/066707A1 |
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...
|
|
WO/2018/060213A1 |
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...
|
|
WO/2018/060438A1 |
Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for ...
|
|
WO/2018/064238A1 |
The addition of a salt to an ALA formulation reduces the degree of burning or irritation from ALA exposure during administration. This is particularly useful for an oral dissolve form of administration due to the extended time of ALA exp...
|
|
WO/2018/060212A1 |
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...
|
|
WO/2018/060704A1 |
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduct...
|
|
WO/2018/060311A1 |
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preve...
|
|
WO/2018/055539A1 |
The invention relates to an aqueous pharmaceutical composition comprising: (a) from about 1 IU/ml to about 500 IU/ml of buffered insulin glargine, and (b) one or more pharmaceutically acceptable excipients, wherein the pharmaceutical com...
|
|
WO/2018/053036A1 |
The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlip...
|
|
WO/2018/046719A1 |
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes...
|
|
WO/2018/047894A1 |
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...
|
|
WO/2018/044468A1 |
Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1α,25- dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidi...
|
|
WO/2018/038803A1 |
The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum alb...
|
|
WO/2018/032787A1 |
A highly glycosylated human growth hormone fusion protein, comprising, from the N-terminus to the C-terminus, of a human growth hormone (hGH), a flexible peptide linker (L), and a human chorionic gonadotropin β-subunit carboxy-terminal ...
|
|
WO/2018/028433A1 |
Provided is a use of Cellular Repressor of EIA-stimulated Genes CREG protein, in particular, provided is a use of the CREG protein or an active fragment thereof in the preparation of medicines for prevention and/or treatment of overweigh...
|
|
WO/2018/028666A1 |
The present application relates a crystal of a compound represented by formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by formula (I), the salt thereof, and t...
|
|
WO/2018/024224A1 |
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...
|
|
WO/2018/026748A1 |
The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyp...
|
|
WO/2018/023003A1 |
Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.
|
|
WO/2018/018097A1 |
The present invention relates to methods of treating mast cell tumors and soft tissue sarcomas using 6,7-epoxy-4,5,9, 12, 13,20-hexahydroxy-l-tigliaen-3-one derivatives in combination with at least one other pharmaceutically active agent...
|
|
WO/2018/015497A2 |
The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The comp...
|
|
WO/2018/010656A1 |
A pyrrolidine derivative serving as a PPAR agonist, and applications thereof in treating diseases of pathways related to a PPAR receptor, such as nonalcoholic steatohepatitis, complication fibrosis, insulin resistance, primary biliary ch...
|
